Efficacy and Safety of Evocalcet Evaluated by Dialysate Calcium Concentration in Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis

References

• Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6:913–921. doi:10.2215/CJN.0604071021454719
   PubMed Web of Science ®Google Scholar
• Komaba H, Kakuta T, Fukagawa M. Diseases of the parathyroid gland in chronic kidney disease. Clin Exp Nephrol. 2011;15:797–809. doi:10.1007/s10157-011-0502-521818548
   PubMed Web of Science ®Google Scholar
• Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) guideline update: what’s changed and why it matters. Kidney Int. 2017;92:26–36. doi:10.1016/j.kint.2017.04.00628646995
   PubMed Web of Science ®Google Scholar
• Rodelo-Haad C, Rodríguez-Ortiz ME, Martin-Malo A, et al. Phosphate control in reducing FGF23 levels in hemodialysis patients. PLoS One. 2018;13:e0201537. doi:10.1371/journal.pone.020153730086150
   PubMed Web of Science ®Google Scholar
• Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69:1945–1953. doi:10.1038/sj.ki.500041416641930
   PubMed Web of Science ®Google Scholar
• van der Sande FM, Ter Meulen KJA, Kotanko P, Kooman JP. Dialysate calcium levels: do they matter? Blood Purif. 2019;47:230–235. doi:10.1159/00049458430517930
   PubMed Web of Science ®Google Scholar
• Fukagawa M, Yokoyama K, Koiwa F, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial. 2013;17:247–288.23735142
   PubMed Web of Science ®Google Scholar
• Pereira L, Meng C, Marques D, Frazão JM. Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes. Clin Kidney J. 2018;11:80–88. doi:10.1093/ckj/sfx12529423207
   PubMed Web of Science ®Google Scholar
• Akizawa T, Shimazaki R, Shiramoto M, Fukagawa M; Evocalcet Study Group. Pharmacokinetics, pharmacodynamics, and safety of the novel calcimimetic agent evocalcet in healthy Japanese subjects: first-in-human Phase I study. Clin Drug Investig. 2018;38:945–954. doi:10.1007/s40261-018-0687-4
   PubMed Web of Science ®Google Scholar
• Akizawa T, Ikejiri K, Kondo Y, Endo Y, Fukagawa M. Evocalcet, a new oral calcimimetic for dialysis patients with secondary hyperparathyroidism. Ther Apher Dial. 2019. doi:10.1111/1744-9987.13434
   Web of Science ®Google Scholar
• Shigematsu T, Shimazaki R, Fukagawa M, Akizawa T. Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan. Clin Pharmacol. 2018;10:101–111. doi:10.2147/CPAA.S17104430254496
   PubMed Web of Science ®Google Scholar
• Shigematsu T, Shimazaki R, Fukagawa M, Akizawa T; Evocalcet Study Group. Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients. Clin Exp Nephrol. 2019;23:258–267. doi:10.1007/s10157-018-1635-630159688
   PubMed Web of Science ®Google Scholar
• Tsuruya K, Shimazaki R, Fukagawa M, Akizawa T; Evocalcet Study Group. Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients. Clin Exp Nephrol. 2019;23:739–748. doi:10.1007/s10157-019-01692-y30955188
   PubMed Web of Science ®Google Scholar
• Kawata T, Tokunaga S, Murai M, et al. A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro. PLoS One. 2018;13:e0195316. doi:10.1371/journal.pone.019531629614098
   PubMed Web of Science ®Google Scholar
• Fukagawa M, Shimazaki R, Akizawa T; Evocalcet study group. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int. 2018;94:818–825. doi:10.1016/j.kint.2018.05.01330049473
   PubMed Web of Science ®Google Scholar
• Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the dialysis outcomes and practice patterns study. Kidney Int. 2005;67:1179–1187. doi:10.1111/j.1523-1755.2005.00185.x15698460
   PubMed Web of Science ®Google Scholar
• Kim HW, Kim SH, Kim YO, et al. Impact of dialysate calcium concentration on clinical outcomes in incident hemodialysis patients. Medicine (Baltimore). 2015;94:e1694. doi:10.1097/MD.000000000000169426448019
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009;76(Suppl 113):S1–130.
   Google Scholar
• Sakai Y, Otsuka T, Ohno D, Murasawa T, Sakai S, Tsuruoka S. Clinical benefit of the change of dialysate calcium concentration from 3.0 to 2.75 mEq/L. Ther Apher Dial. 2014;18:181–184. doi:10.1111/1744-9987.1209924720409
   PubMed Web of Science ®Google Scholar
• Iseki K, Henn LL, Nomura T, et al. Dialysate calcium concentration below 3.0 mEq/L is not associated with improved outcomes in the Japanese Dialysis Outcomes and Practice Patterns Study. Nephron. 2018;140:240–248. doi:10.1159/00049347030343299
   PubMed Web of Science ®Google Scholar
• Kawanishi H, Moriishi M, Takahashi N, Tsuchiya S. The central dialysis fluid delivery system (CDDS): is it specialty in Japan? Ren Replace Ther. 2016;2:1. doi:10.1186/s41100-016-0016-4
   Google Scholar
• Matsuura A, Inaguma D, Itawaki D, et al. The change of the dialysate calcium concentration from 3.0 to 2.75 mEq/L did not affect the serum PTH level in hemodialysis patients. J Jpn Soc Dial Ther. 2012;45:873–880. doi:10.4009/jsdt.45.873.
   Google Scholar
• Shinkai N, Yanase M, Kyoda Y, et al. Effects of dialysate calcium concentration on calcium-phosphorus metabolism in hemodialysis patients. J Jpn Soc Dial Ther. 2010;43:933–938. doi:10.4009/jsdt.43.933.
   Google Scholar
• Yokoyama K, Shimazaki R, Fukagawa M, Akizawa T; Evocalcet Study Group. Long-term efficacy and safety of evocalcet in Japanese patients with secondary hyperparathyroidism receiving hemodialysis. Sci Rep. 2019;9:6410. doi:10.1038/s41598-019-42017-z31015494
   PubMed Web of Science ®Google Scholar
• Yokoyama K, Kagami S, Ohkido I, et al. The negative Ca(2+) balance is involved in the stimulation of PTH secretion. Nephron. 2002;92:86–90. doi:10.1159/00006448412187089
   PubMed Web of Science ®Google Scholar
• Susantitaphong P, Vadcharavivad S, Susomboon T, et al. The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism. Ren Fail. 2019;41:326–333. doi:10.1080/0886022X.2018.156235631014177
   PubMed Web of Science ®Google Scholar
• Shigematsu T, Fukagawa M, Yokoyama K, et al. Effects of the intravenous calcimimetic etelcalcetide on bone turnover and serum fibroblast growth factor 23: post hoc analysis of an open-label study. Clin Ther. 2018;40:2099–2111. doi:10.1016/j.clinthera.2018.10.01630473399
   PubMed Web of Science ®Google Scholar
• Moe SM, Chertow GM, Parfrey PS, et al. Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. Circulation. 2015;132:27–39. doi:10.1161/CIRCULATIONAHA.114.01387626059012
   PubMed Web of Science ®Google Scholar
• Gutiérrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584–592. doi:10.1056/NEJMoa070613018687639
   PubMed Web of Science ®Google Scholar
• Martin A. Bone and heart health in chronic kidney disease: role of dentin matrix protein 1. Curr Opin Nephrol Hypertens. 2019;28:297–303. doi:10.1097/MNH.000000000000051231107286
   PubMed Web of Science ®Google Scholar
• Tentori F, Wang M, Bieber BA, et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol. 2015;10:98–109. doi:10.2215/CJN.1294121325516917
   PubMed Web of Science ®Google Scholar